Sirnaomics, Inc. is a biopharmaceutical company developing novel targeted therapeutics for critical human diseases using RNA interference (RNAi) technology. SBIR-involved in its early years but not more recently, the firm is headquartered in Gaithersburg, having facilities in Cambridge, MA and Suzhow China. Working on enhancement of the potency of active pharmaceutical ingredient (API) using multi-targeted small interfering RNA (siRNA) cocktail, improvement of the API in vivo delivery using clinical viable synthetic polymeric and lipid nanoparticles. The name of the company Sirnaomics (/ser-'now-miks/) is derived from the molecular terminology "siRNA" with the suffix "-omics" to signify the bridge between the study of the structure and function of small interfering RNAs (including their gene silencing properties) and the molecular comprehension of the complex interplay between genes these molecules target and pathways implicated in disease. With a focus on becoming a leader in the field of siRNA therapeutics with strong technology platforms for siRNA drug design and delivery system development, the company has established partnerships with multinational pharmaceutical and major biopharmaceutical companies. Using multi-targeted siRNA cocktail design and three-generation nanoparticle-based delivery systems the company has discovered and developed an enriched siRNA therapeutic product pipeline. The siRNA therapeutic programs at the late stage of preclinical development include a novel approach for improvement of scarless wound healing (STP705), a dual-targeted therapeutic (STP601) for treatment of diabetic retinopathy and AMD (age-related macular degeneration), a âresistance-proofâ siRNA therapeutic for treatment of Influenza infection (STP702), and a cancer siRNA therapeutics (STP503) for treatment of breast cancer, e
